Pomalidomide-amido-C4-amido-C6-NH-Boc is primarily utilized in the development of PROTACs (Proteolysis Targeting Chimeras), a cutting-edge technology in drug discovery. This compound serves as a key linker molecule, connecting the target protein-binding moiety with the E3 ubiquitin ligase-recruiting moiety. Its structure allows for precise control over the degradation of specific disease-causing proteins, making it valuable in cancer research, particularly for targeting proteins resistant to traditional therapies. Additionally, it is employed in the synthesis of small molecules for studying protein-protein interactions and exploring novel therapeutic pathways. Its Boc-protected amine group ensures stability during chemical reactions, facilitating its use in complex organic syntheses.